Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company"), announces that it has filed documentation with the European Medicines Agency ("EMA") in relation to its request for re-examination of the marketing approval application ("MAA") for Cerepro®, Ark's novel gene based therapy for the treatment of operable malignant glioma (brain cancer). The EMA have acknowledged receipt of the filing. The re-examination filing provides evidence from the Phase III trial (Study 904) in relation to possible bias in the decision to re-intervene, and the validity of the endpoint...
More...
More...